The Russian company Pharmasyntez intends to bring 3 innovative domestic drugs to the market in 2025-2026, said Vikram Punia, the owner of the group, at the 32nd N.A. Semashko Russian Pharmaceutical Forum.
“This year and possibly in the first half of 2026, we will launch 3 new innovative drugs onto the market. In fact, all three have the potential to become blockbusters in their fields,” he said.
In particular, Pharmasyntez is preparing to launch Vamotinib (vamotinib) – the first original third-generation tyrosine kinase inhibitor (TKI) for treating patients with chronic myeloid leukemia (CML) who are resistant to prior therapies. Clinical trial data confirm its high efficacy and favorable safety profile. The drug’s development took approximately seven years. Pharmasyntez believes Vamotinib has global market potential and has already submitted registration documents to the national regulatory authority.
“I can virtually guarantee that this drug will generate foreign currency revenue exceeding one billion euros,” added the company’s president.
The Russian company plans to launch Serogard (adesmapimod vimdemer). As Punia noted, this is the world’s first innovative drug for preventing adhesive disease. This disease causes numerous complications each year, including life-threatening ones, and often necessitates repeat surgical interventions.
The third product scheduled for release in the Russian market is Saterax, Russia’s first original dipeptidyl peptidase-4 (DPP-4) inhibitor for treating type 2 diabetes. According to the president of Pharmasyntez Group, this medication addresses the critical need for modern, safe treatment options as part of import substitution efforts.
Earlier, Pharmasyntez announced its financial results for 2024. The company’s consolidated revenue under RAS in 2024 went up by 35% compared to 2023, reaching 50.1 billion rubles. Earnings before interest, taxes, depreciation, and amortization (EBITDA) in 2024 amounted to 8.7 billion rubles. The company registered and marketed 25 new drugs last year.
